Drugs / anti-GPC3 CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02395250 | Mar 2015 → Jun 2016 | hepatocellular carcinoma | RenJi Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-GPC3 CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02395250 ↗ |
| Modality | Cell therapy | “autologous T cells bearing chimeric antigen receptor” NCT02395250 ↗ |
| Target | GPC3 | “specifically recognize glypican-3 (GPC3)” NCT02395250 ↗ |